Episode 73: ESMO 2023 - Genitourinary Cancers - Prostate and Bladder

Genitourinary cancers come in all shapes and sizes, and this year, ESMO2023 takes the research up a notch. Prostate cancer is centre stage, and you might ask why, as it boasts extraordinary overall survival and progression-free survival. The issue lies in the sequencing of therapies and how to make treatment durable and better tolerated for all. Third, immunotherapy is not ready for primetime in this cohort of patients, and the reasons are unclear. Not to be outdone, bladder cancer continues to make strides in patient care with a phase 1 study that may be lost in no-man land or could harbour a shift in trial design with antibody drug conjugates. Today, we discuss the following trials:

Articles discussed in this episode. Subscription may be required:

·      Keynote 641 (Pembrolizumab + enzalutamide in the metastatic castrate-resistant prostate cancer sphere)

o   https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2819%2930688-6/fulltext

·      PSMAfore trial (LuPSMA in taxane naive patients)

o   https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639061

·      MAGNITUDE Study (Niraparib and abiraterone)

o   https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639153

·      The DAD study (sacituzumab govitecan (SG) plus enfortumab vedotin (EV))

o   https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00563-6/fulltext